全文获取类型
收费全文 | 49865篇 |
免费 | 4053篇 |
国内免费 | 1397篇 |
专业分类
耳鼻咽喉 | 623篇 |
儿科学 | 1424篇 |
妇产科学 | 1034篇 |
基础医学 | 6678篇 |
口腔科学 | 1124篇 |
临床医学 | 4814篇 |
内科学 | 8446篇 |
皮肤病学 | 1011篇 |
神经病学 | 3940篇 |
特种医学 | 2249篇 |
外国民族医学 | 19篇 |
外科学 | 7273篇 |
综合类 | 4360篇 |
现状与发展 | 4篇 |
一般理论 | 6篇 |
预防医学 | 3081篇 |
眼科学 | 941篇 |
药学 | 3511篇 |
31篇 | |
中国医学 | 1230篇 |
肿瘤学 | 3516篇 |
出版年
2023年 | 490篇 |
2022年 | 748篇 |
2021年 | 1491篇 |
2020年 | 1339篇 |
2019年 | 1165篇 |
2018年 | 1282篇 |
2017年 | 1182篇 |
2016年 | 1318篇 |
2015年 | 1654篇 |
2014年 | 2030篇 |
2013年 | 2390篇 |
2012年 | 3358篇 |
2011年 | 3436篇 |
2010年 | 2192篇 |
2009年 | 1989篇 |
2008年 | 2629篇 |
2007年 | 2679篇 |
2006年 | 2495篇 |
2005年 | 2313篇 |
2004年 | 1879篇 |
2003年 | 1868篇 |
2002年 | 1587篇 |
2001年 | 1348篇 |
2000年 | 1232篇 |
1999年 | 975篇 |
1998年 | 436篇 |
1997年 | 361篇 |
1996年 | 283篇 |
1995年 | 281篇 |
1994年 | 262篇 |
1993年 | 220篇 |
1992年 | 541篇 |
1991年 | 550篇 |
1990年 | 523篇 |
1989年 | 438篇 |
1988年 | 413篇 |
1987年 | 436篇 |
1986年 | 432篇 |
1985年 | 424篇 |
1984年 | 296篇 |
1983年 | 233篇 |
1982年 | 158篇 |
1981年 | 161篇 |
1979年 | 279篇 |
1978年 | 188篇 |
1976年 | 160篇 |
1975年 | 169篇 |
1974年 | 195篇 |
1973年 | 172篇 |
1972年 | 159篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
2.
Hommes Franziska Mohsenpour Amir Kropff Dana Pilgram Lisa Matusall Svenja von Philipsborn Peter Sell Kerstin 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(1):96-106
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Akteure der öffentlichen Gesundheit (Public Health) tragen wesentlich zu Gesundheitsschutz, -förderung und... 相似文献
4.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
5.
目的 对已公开发表的新冠肺炎核心指标集及其研究方法进行比较分析,为临床试验和证据转化研究提供参考信息。方法 计算机检索COMET数据库,并补充检索CNKI、WanFang、PubMed、Web of Science、The Cochrane Library等数据库,收集发表的新型冠状病毒肺炎(Coronavirus Disease 2019,COVID-19)核心指标集(Core Outcome Set,COS)研究,检索时间截至为2021年3月31日。按照纳入排除标准筛选文献,并提取研究基本信息、研究方法及指标数据,对其进行描述性分析。结果 共纳入5项COVID-19核心指标集相关研究(4项为COVID-19-COS研究,1项为COVID-19核心指标测量工具研究)。相同的结局指标包括死亡率、病毒核酸检测、临床进展、恢复期、临床症状评分及临床分型等。指标来源主要来自临床试验注册平台和问卷调查;达成共识的方法主要采用共识会议;利益相关群体中临床专家、方法学专家和医疗管理人员涉及较多。结论 不同的新冠肺炎核心指标集研究有一定的共性,但由于应用场景不同,也存在一定差异。随着对疾病认识的深化,相关COVID-19核心指标需要加强测量方法和疗程推荐。 相似文献
6.
With the advance of genome engineering technology, chimeric antigen receptors (CARs)-based immunotherapy has become an emerging therapeutic strategy for tumors. Although initially designed for T cells in tumor immunotherapy, CARs have been exploited to modify the function of natural killer (NK) cells against a variety of tumors, including hepatocellular carcinoma (HCC). CAR-NK cells have the potential to sufficiently kill tumor antigen-expressing HCC cells, independent of major histocompatibility complex matching or prior priming. In this review, we summarize the recent advances in genetic engineering of CAR-NK cells against HCC and discuss the current challenges and prospects of CAR-NK cells as a revolutionary cellular immunotherapy against HCC. 相似文献
7.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
8.
Alessandro Rambaldi Alessandra Iurlo Alessandro M. Vannucchi Bruno Martino Attilio Guarini Marco Ruggeri Nikolas von Bubnoff Marianna De Muro Mary Frances McMullin Stefania Luciani Vincenzo Martinelli Axel Nogai Vittorio Rosti Alessandra Ricco Paolo Bettica Sara Manzoni Silvia Di Tollo 《Blood cancer journal》2021,11(3)
9.
Yang Luan Yan Zhang Kai Cui Fan Li Baolong Qin Yajun Ruan Kun Tang Hongyang Jiang Hao Li Xiaoyi Yuan Zhuo Liu Xiaming Liu Gan Yu Shengfei Xu Ruibao Chen Huan Yang Xiaolin Guo Xiaoyong Zeng Zhong Chen Zhiqiang Chen Zhiquan Hu Xiaodong Song Zhihua Wang Shaogang Wang Jihong Liu Tao Wang 《Translational andrology and urology》2021,10(1):466
BackgroundTo introduce and determine the value of optimized strategies for the management of urological tube-related emergencies with increased incidence, complexity and operational risk during the global spread of coronavirus disease 2019 (COVID-19).MethodsAll emergent urological patients at Tongji Hospital, Wuhan, during the period of January 23 (the beginning of lockdown in Wuhan) to March 23, 2020, and the corresponding period in 2019 were recruited to form this study’s COVID-19 group and control group, respectively. Tongji Hospital has the most concentrated and strongest Chinese medical teams to treat the largest number of severe COVID-19 patients. Patients in the control group were routinely treated, while patients in the COVID-19 group were managed following the optimized principles and strategies. The case incidence for each type of tube-related emergency was recorded. Baseline characteristics and management outcomes (surgery time, secondary complex operation rate, readmission rate, COVID-19 infection rate) were analyzed and compared across the control and COVID-19 periods.ResultsThe total emergent urological patients during the COVID-19 period was 42, whereas during the control period, it was 124. The incidence of tube-related emergencies increased from 53% to 88% (P<0.001) during the COVID-19 period. In particular, the incidence of nephrostomy tube-related (31% vs. 15%, P=0.027) and single-J stent-related problems (19% vs. 6%, P=0.009) increased significantly. The mean surgery times across the two periods were comparable. The number of secondary complex operations increased from 12 (18%) to 14 (38%) (P=0.028) during the COVID 19-period. The number of 2-week postoperative readmission decreased from 10 (15%) to 1 (3%) (P=0.049). No participants contracted during the COVID-19 period.ConclusionsUrological tube-related emergencies have been found to have a higher incidence and require more complicated and dangerous operations during the COVID-19 pandemic. However, the optimized management strategies introduced in this study are efficient, and safe for both urologists and patients. 相似文献
10.
Improving hyperpolarized 129Xe ADC mapping in pediatric and adult lungs with uncertainty propagation